Hospitals urge Congress to scrap $8B in cuts as shutdown looms

Molly Gamble 

More than 250 hospitals and health systems are urging Congress to halt the $8 billion reduction to Medicaid disproportionate share hospital funding, set to begin Oct. 1.

The funding cuts, part of the Affordable Care Act, will curb Medicaid DSH funding by $8 billion in fiscal years 2024 through 2027 — a $32 billion reduction total. In their Sept. 14 appeal to Congress, safety-net hospitals urged lawmakers to “eliminate, at a minimum” the $16 billion in cuts scheduled for fiscal years 2024 and 2025. 

The Medicaid DSH program, established in the 1980s, provides financial support to hospitals that serve a significantly disproportionate number of low-income patients and the under- and uninsured.

“The need for DSH funding is even greater now, as hospital expenses per patient have increased significantly since the pandemic,” the hospitals, represented by the association America’s Essential Hospitals, wrote to Congress. They said ongoing high levels of uncompensated care nationwide make Medicaid DSH cuts indefensible.

The American Hospital Association has noted, in separate communication, that the scheduled cuts would coincide with a “difficult transition” for the Medicaid program, as states are reviewing eligibility and disenrolling people who no longer qualify for Medicaid after the COVID-19 public health emergency ended in May. 

The ACA included Medicaid DSH cuts under the reasoning that hospitals would care for fewer uninsured patients as health insurance coverage expanded. Congress has previously staved off the cuts 11 times, in bipartisan fashion. 

Hospitals’ appeal comes as Congress hurries to wrap up its appropriations process and pass a funding bill by Sept. 30. Inability to pass a funding bill could result in a partial or complete shutdown of the federal agency and services and risk programs due to end at the end of the fiscal year without Congressional action. The House of Representatives is preparing for a Republican-led continuing resolution — a stopgap bill that would extend the funding deadline by one month — that is unlikely to proceed in the Democrat-controlled Senate. 

Hospitals urge Congress to scrap $8B in cuts as shutdown looms (beckershospitalreview.com)

Methodist invests $75M to reopen shuttered Texas hospital

Noah Schwartz 

San Antonio-based Methodist Healthcare System invested $75 million to reopen a shuttered San Antonio hospital before the end of the month, San Antonio Business Journal reported Sept. 18.

The hospital, formerly known as Forest Park Medical Center, has been closed since 2015. The COVID-19 pandemic delayed Methodist’s construction and reopening plans. 

After redevelopment, the new Methodist Hospital Landmark location will have 54 beds, 12 operating rooms and 27 private patient rooms. 

“All of the Methodist Healthcare hospitals are dealing with capacity challenges due to growth in the market and demand for our services,” Methodist Hospital Landmark CEO Ryan Simpson told the Journal. “This facility allows us to have more capacity as a system. It happens to be in a growing part of the city.”

14 drugs now in shortage

Paige Twenter 

While some hospitals are paying five to 10 times more for cancer drugs during a monthslong shortage, the U.S. saw 14 new drug supply issues since early August. 

Here are 14 new drug shortages, according to data from the FDA and the American Society of Health-System Pharmacists. 

Editor’s note: The drugs are listed in alphabetical order.

1. Alfuzosin extended-release tabletsThree solutions are unavailable and two are available, and the shortage is predicted to recover in August. The drug relaxes a patient’s bladder and prostate muscles. 

2. Atropine sulfate ophthalmic ointmentBausch Health is reporting a short-term shortage of the medication that’s used to dilate the pupil before eye exams. The company is the sole supplier of the solution and did not share an estimated release date. 

3. Azacitidine injections: Three drugmakers stopped making 100 milligram solutions of the leukemia drug. 

4. Collagenase ointmentsThere is not enough supply for usual ordering of the ointment that’s used to treat burned skin and skin ulcers as Smith & Nephew has two solutions on intermittent back order without a release date.

5. Glipizide XL tabletsPfizer discontinued manufacturing the Type 2 diabetes drug. 

6. Ibuprofen and famotidine tablets: Teva Pharmaceuticals and Horizon Therapeutics discontinued manufacturing the painkiller. 

7. Iobenguane I-131 injections: Progenics Pharmaceuticals stopped making two solutions because of low demand for the oncology medication. 

8. Iodine and potassium iodide topical solutions: Two solutions of the dermatology drug are in shortage and one solution is available. Cooper Surgical could not estimate a resupply date, and Gordon Laboratories predicted mid-September. 

9. Nitroglycerin injections: One solution of the hypertension drug is available as three others are in limited supply without a release date. 

10. Nystatin topical powderPadagis has two solutions of the antifungal medication on allocation through October and one on intermittent back order. No other solutions are available. 

11. Pamidronate disodium injections: Five solutions of the drug that treats bone fragility are in shortage. Viatris said it expects two products to return to normal supply levels in September, and Pfizer predicted resupply between October and January for its three solutions. 

12. Piroxicam capsules: Pfizer said it is discontinuing production of the painkiller. Supply of the 20 milligram solutions is expected to last until October. 

13. Tedizolid injectionsAs operations wind down at Nabriva Therapeutics and transition to Merck, there’s insufficient supply of the bacterial skin infection drug. Resupply is expected in late August.

14. Theophylline 24-hour extended-release capsules and tabletsSix solutions of the lung disease medication are on back order and two are available. Rhodes Pharmaceuticals could not forecast a resupply date for two of its solutions, and Endo Pharmaceuticals predicted its shortage to end in October. 

14 drugs now in shortage (beckershospitalreview.com)

‘It’s ridiculous’: Why hospitals pay millions to get paid electronically

Giles Bruce 

Hospitals and physicians are paying millions of dollars for a hidden fee to receive reimbursement from payers electronically, ProPublica reported Aug. 15.

Payers and middlemen charge healthcare providers as much as 5 percent to process electronic payments, according to the story. The ACA required payers to offer electronic funds transfers and nudged physicians to take them. CMS at one time prohibited the processing fees before reversing course.

Tim Reiner, senior vice president of revenue management of Altamonte Springs, Fla.-based AdventHealth, complained to CMS about the fees in 2020, the news outlet reported. “I have to pay $1.8M in expenses that I could use on PPE for our employees, or setting up testing sites, or providing charity care, or covering other community benefits,” he wrote.

“It’s ridiculous,” Karen Jackson, a retired senior CMS official, told the news outlet.

The U.S. Department of Veterans of Affairs has declined to pay the fees, declaring them illegal, according to the story.

The pushback against the fees has been led by Alex Shteynshlyuger, MD, a private urologist in New York City, while the campaign to keep them has been spearheaded by Matthew Albright, chief lobbyist at payment processing company Zelis, according to the article. Mr. Albright, a former CMS official, had pressed CMS on getting rid of its ban on the fees. The agency told ProPublica it had no legal authority to outlaw the fees, adding that it “receives feedback from a wide range of stakeholders on an ongoing basis.”

Other electronic payment vendors include UnitedHealth Group subsidiaries Change Healthcare and VPay. UnitedHealth told ProPublica the companies cut down on administrative burden and speed up payments for providers. Zelis told the news outlet that it helps prevent “many of the obstacles that keep providers from efficiently initiating, receiving, and benefitting from electronic payments.”

‘It’s ridiculous’: Why hospitals pay millions to get paid electronically (beckershospitalreview.com)

Pfizer announces post-tornado relief plans for Rocky Mount community and manufacturing facility 

July 24, 2023 – Pfizer announced immediate efforts to provide relief and repair the damage caused to its manufacturing facility in Rocky Mount, North Carolina after a violent tornado swept through the town on Wednesday, July 19. All 3,200 local Pfizer colleagues reporting to this manufacturing site are safe and accounted for after excellent implementation of the site’s long-standing evacuation plan. Crews are working around-the-clock to restore power, assess the structural integrity of the building and move finished medicines to nearby sites for storage. 

Pfizer also announced a donation to the American Red Cross North Carolina Chapter and United Way Tar River Region to support the relief and recovery needs. Additionally, the Pfizer Foundation will match employee donations to these organizations. 

The site is closed while the damage is assessed. Pfizer is committed to rapidly restoring full function to the site, which plays a critical role in the U.S. healthcare system. This effort is in close partnership with the U.S. Food and Drug Administration Commissioner Robert Califf, North Carolina Governor Roy Cooper as well as other state, local and federal officials. 

Most of the damage was caused to the warehouse facility, which stores raw materials, packaging supplies, and finished medicines awaiting release by quality assurance. Pfizer is working diligently to move product to other nearby sites for storage and to identify sources to replace damaged raw materials and supplies. Pfizer is also exploring alternative manufacturing locations for production across our significant manufacturing presence in the U.S. and internationally and across the company’s partner network. After an initial assessment, there does not appear to be any major damage to the medicine production areas. 

Since 1968, the Rocky Mount facility has been a key producer for sterile injectables. Currently, it is responsible for manufacturing nearly 25 percent of all Pfizer’s sterile injectables – including anesthesia, analgesia, therapeutics, anti-infectives and neuromuscular blockers – which is nearly 8 percent of all the sterile injectables used in U.S. hospitals. The site is one of 10 Pfizer manufacturing sites located in the United States. 

Learn More 

Pfizer announces post-tornado relief plans for Rocky Mount community and manufacturing facility (repertoiremag.com)

Increasing American Manufacturing in the Wake of COVID-19

July 2023- The Journal of Healthcare Contracting

In the constant search for ways to cut costs across the board, one of the biggest points of debate for IDNs and providers is the decision between domestic or international manufacturing for their supplies. The pandemic illuminated the need for increased manufacturing in the United States as the demand for PPE and other materials skyrocketed. Companies without any onshore manufacturing were much more likely to struggle with sourcing materials for their clients, but the labor and raw material costs make domestic manufacturing harder to maintain for others. Essentially, it comes down to the needs and goals of the company.

The Journal of Healthcare Contracting publisher John Pritchard recently sat down with several supply chain leaders to discuss the merits of investing in U.S.-based manufacturing for providers:

  • Rene Gurdian, Assistant Vice President of Supply Chain Finance and Strategy at Ochsner Health
  • George Godfrey, Chief Supply Chain Officer at Baptist Health South Florida
  • Bob Boswell, President and CEO at LeeSar & Cooperative Service of Florida
  • John Wood, CEO of Encompass

Changing sourcing strategies after COVID

Because of the pressures that COVID created for the healthcare supply chain, many organizations had to look for new sourcing strategies to improve supply chain assurance across the board. The biggest thing we learned from COVID is the lack of transparency and visibility around distribution and manufacturing, which led to the discovery of counterfeit products that did not meet the compliance standards required for their use in a healthcare setting. “We didn’t know where they were coming from. We didn’t know what types of challenges we were coming up against overseas,” Gurdian said.

At Ochsner, their Supply Chain leadership group has invested in several resiliency tools to better understand the bill of materials outside of the United States. This information provides their supply chain an improved transparent landscape that provides insight into the raw materials Ochsner is purchasing, which provides an opportunity to align long-term contingency plans on potential upcoming disruptions. Gurdian said, “At Ochsner, our overarching goal is to try to educate our team members, whether it’s a par technician or a contract analyst, that while  [these individuals] are not at the beside directly, we are five to six degrees separated and we can potentially impact patient experience as well in tandem with the clinical experience.”

Patient care is of course the top priority, and that starts in places like supply closets. With the labor challenges facing healthcare within the nursing community, Gurdian used the example of hard-working nurses that need to spend time taking care of their patients, but that time is limited when they cannot locate the right products in the right place due to disheveled supply closets. “At Ochsner, we pride ourselves on the format of PAR closets (supply closets) and products being in a place that nurses can quickly locate the product and return to the bedside to be with their patients.”

Godfrey’s team at Baptist Health is among the many that have struggled with item substitutions in the last few years. These companies that struggled with item substitutions faced prices that increased as high as 200% for out-of-contract transactions. When organizations like Baptist Health are tied up in a contract that cannot procure the items they need, they have to source the items on an off-contract basis.

“Historically, supply chains don’t have the reporting capabilities to understand the complexities in item substitutions,” Godfrey said. “We go through contract renewals; we have a process in place. We understand increases and decreases, but when it comes to item substitution and you are in the hand-to-hand combat of getting supplies for the patients, the tools and analysis are not robust.”

The application of technology can be tricky when it comes to the human element of your organization. Automating your processes and applications after COVID might seem like an obvious choice to make, but it shouldn’t be at the expense of your team.

Godfrey said, “We look at technology not to replace people, but more to enable our people to do an outstanding job at what they are called to do. Whether it’s using technology for workload management or deploying supplies into one of the 1,100 supply cabinets we manage across 12 hospitals, we try to be innovative at everything we do. Additionally, if we are trying to drive success in certain areas, we are trying to measure success as we go along.”

Other organizations decided to improve their predictive analytics to improve their sourcing processes. At LeeSar, Boswell said through predictive analytics, they were able to leverage material resource planning capacity. He said, “We started leveraging more technology and freeing up our sourcing specialists and buyers to focus more on back orders. We also generate a daily pulse report that is a byproduct of our IT system. With this pulse report, we know the status of all inventory locations, current backorder and auto-sub status, raw and adjusted fill rates.”

Changing manufacturing processes after COVID

Sourcing strategies are among many things that have changed in the wake of COVID-19. If American manufacturing is going to be a viable option for providers going forward, there are things that need to change to make it more available for providers.

One of the biggest challenges facing domestic manufacturing is finding the people to fill these jobs. Labor costs and operational costs are higher for domestic manufacturing, but these costs can be offset with improved quality standards and smaller shipping windows.

For Encompass, John Wood and his team are considering shifting their manufacturing processes to nearshore instead of onshore.

“We have manufacturing in the U.S., but we have a big focus on moving to nearshore,” Wood said. “The mission for Encompass is really focused on the fact that we believe every patient, resident, caregiver, and family member needs to feel safe and comfortable in the healthcare environment. Safety is the biggest part of that, and the way we can assist people is by creating innovative products that are reliably delivered and cost effective.”

Nearshore sourcing allows for improved shipping windows from offshore sourcing. Wood said that a facility in China would have to guess what customers need three months in advance, but a nearshore facility in Mexico could drastically reduce that window.

From Wood’s perspective, COVID has forced his team to be better at what they do. “The big problem through COVID was the difference in lag time in the cost system. On the manufacturing side, we were getting price increases six months before.”

Wood believes whatever challenges that providers face in supply chain are due to “something in the chain that shouldn’t be there,” not because the healthcare industry is erratic. He said, “It’s complicated, right? You’ve got distributors, manufacturers, providers, GPOs. It’s become quite a complex system. I would say we do a better job with our direct IDNs because we have salespeople who go out and help us implement programs.”

The future of American manufacturing

Are we prepared for another pandemic? Another supply chain gridlock? What happens if another significant disruption upsets the balance again? The answer is complicated, but introducing more American manufacturing could be the key to avoiding some of the challenges that came from the coronavirus pandemic.

Gurdian said, “I think what we’ve learned is that there was a lack of transparency and education between the sales side of the suppliers to the supply chain side of the suppliers. I can sell products all day, but that doesn’t mean that I know how it’s made or where it comes from. What I’ve requested from any of the vendors that we talk to is to make sure that their team feels empowered to get some cross education with their peers in their organization within their organization’s supply chain department to really understand the products they are selling. It’s great to get a sale, but it’s not good if the product doesn’t show up.”

There’s of course a bit of give and take when it comes to engaging in domestic manufacturing. Onshoring manufacturing for healthcare companies will require higher labor and operational expenses, but it will also ensure the quality of the material and decrease shipping rates. Being able to visit the facilities for quality checks is a huge bonus for buyers, and it would have been a major advantage for healthcare organizations that were struggling with counterfeit products during the height of the pandemic. Ocean freight prices are astronomical, and it takes much longer for supplies to get in from an offshore source.

Another thing to consider for those looking to make a switch is the performance of their suppliers. Have you had difficulties in getting the supplies you needed? The quality of your supplier is a huge component to the success of your organization. “What we look at is supplier performance,” Godfrey said. “We are trying to move business away from the suppliers that do not manage their business very well.”

“At the end of the day, the most important thing is that patient care is not being compromised. Our first priority is to secure the supplies regardless of the source. In doing this there is a natural migration to the better performing and more consistent suppliers. Noble intentions are to support more domestic manufacturing and suppliers; the reality is that currently there are cost factors and limited supply in that space,” Boswell said.

Increasing American Manufacturing in the Wake of COVID-19 – The Journal of Healthcare Contracting (jhconline.com)

CMS floats 2.2% cut to home health payments in 2024

Alan Condon 

CMS has proposed a 2.2 percent pay cut for home health providers next year, or an estimated $375 million less than 2023 levels.

Four things to know:

1. The proposed rule would increase payments to 2.7 percent, or $460 million, but home health agencies would see a 5.1 percent decrease that reflects the effects of the permanent behavior assumption adjustment (a $870 million decrease) and an estimated 0.2 percent increase for a proposed update to the fixed-dollar loss ratio used in determining outlier payments (a $35 million increase).

2. For 2024, using updated 2022 claims and the methodology finalized in the 2023 rule, CMS determined that it paid more under the new system than it would have under the old system. So, the agency is proposing an additional permanent adjustment percentage of -5.653 percent in 2024 to address the differences in the aggregate expenditures.

3. CMS is proposing to adopt two new measures for the home health quality reporting program in 2025, including a measure on the percentage of patients who are up to date with their COVID-19 vaccinations. The agency also proposed various changes to the measures used in the Home Health Value-based Purchasing program and the weighting methodology used to score performance and payment adjustments in the program. 

4. The proposed rule is expected to be published in the Federal Register on July 10, with CMS accepting comments on the draft through Aug. 29. 

Click here for more details on the proposed rule.

CMS floats 2.2% cut to home health payments in 2024 (beckershospitalreview.com)

CMS rule could strip Texas Medicaid of $8.4B, lawmakers say.

Alan Condon – Friday, June 9th, 2023

Texas lawmakers have condemned a federal rule that could see the state lose about $8.4 billion in Medicaid funding, Allied News reported June 8. 

A memo published by CMS in February aims to end payment agreements between Texas and hospitals in the state. Texas taxes hospitals to pay for Medicaid costs, and then gives hospitals funds it receives from the federal government to cover the incurred taxes, according to the report. 

Texas hospitals also share their Medicaid funds to help hospitals that care for a higher proportion of low-income patients, but the federal memo targets this arrangement as illegal, according to NBC affiliate KXAN.

Texas is also the uninsured capital of the U.S., with more than 4.3 million Texans, 18.4 percent of residents, going without health insurance, according to the Texas Medical Association, which says state uninsurance rates — 1.75 times the national average — create significant problems in the financing and delivery of care.

“For 40 years, we’ve had a good system where the state and the federal government cooperate with healthcare providers to provide care,” Texas State Sen. Bryan Hughes said during a June 7 news conference. “But now, because of changes proposed by unelected bureaucrats, this whole system is in jeopardy.” 

In April, states began disenrolling people from Medicaid after the expiration of a COVID-19 policy that allowed for continuous enrollment. As a result, an estimated 18 million people across the country will lose Medicaid coverage by June 2024, and 3.8 million of those will become uninsured, according to the Urban Institute and the Robert Wood Johnson Foundation. More than 1.2 million Texas are projected to be disenrolled over the next 12 months. 

“CMS’ proposed rule would devastate the healthcare safety net at the expense of Texas’’ poorest residents, including low-income pregnant women, children and seniors,” John Hawkins, CEO of the Texas Hospital Association, told Becker’s. “Already navigating the challenge of carrying the nation’s highest rate of uninsured residents, Texas relies on its Medicaid program to make sure low-income Texans can access care in all corners of the state. This rule is the latest in a series of attacks on long-standing methods CMS has permitted states to use to finance their Medicaid programs. We are unclear why CMS has chosen to revive this position after it withdrew the roundly maligned Medicaid Fiscal Accountability Rule in early 2021.”

CMS rule could strip Texas Medicaid of $8.4B, lawmakers say (beckershospitalreview.com)

Texas closes ‘Dr. Death’ loophole

Ashleigh Hollowell 

Texas Gov. Greg Abbott signed a bill into law June 13 aimed at improving patient safety by closing a longstanding loophole that allowed an infamous physician to keep practicing despite concerns of harm being done to patients, NBC affiliate KXAN reported.

The physician, nicknamed Dr. Death, was sentenced to life in prison in 2017 after being found guilty of harming or killing more than 30 patients. Despite concerns and because of gaps in reporting and monitoring in the National Practitioner Data Bank, he was allowed to continue practicing at multiple locations before his arrest.

The new bill, HB 1998, seeks to equip the Texas Medical Board with necessary tools to protect patients from dangerous physicians while also maintaining transparency about physician disciplinary records.


Here’s what else the new law will enforce

  1. Lying on medical license applications will be a Class A misdemeanor.
  2. Physicians who have been convicted of a felony or misdemeanor related to moral turpitude are not allowed to practice medicine in the state.
  3. Physicians who have had a medical license revoked, restricted or suspended in another state are not allowed to practice medicine in the state.
  4. Monthly monitoring of physicians will be required using the National Practitioner Data Bank — which KXAN describes as “a confidential clearinghouse of all physician complaints, established by Congress.”  The complaints are not publicly available.
  5. The Texas Medical Board must update physician profiles on its website within 10 days of being notified about any disciplinary action against a physician.

Becker’s reached out to the Texas Medical Board for its comment on the passage of the legislation and will update this story if new information is provided.

Texas closes ‘Dr. Death’ loophole (beckershospitalreview.com)

Hospitals Experiencing Effects of Inflation and End of Public Health Emergency

Kaufman Hall analysis illustrates financial effects of inflation and the end of the COVID-19 public health emergency

CHICAGO – May 31ST, 2023 – Hospital finances broke even in April amid a continuing trend of high expenses and the unwinding of the Medicaid continuous coverage requirement of the COVID-19 public health emergency (PHE), according to the latest National Hospital Flash Report from Kaufman Hall.

Median YTD Operating Margin Shows Slight Improvement

The median year-to-date (YTD) operating margin index for hospitals was 0.0% in April, up slightly compared to -0.3% in March. With operating margins remaining at or below zero, hospitals have been left with little financial flexibility.

PHE Unwinding Begins

Hospitals experienced increases in bad debt and charity care in April. Combined with decreased patient volumes, Kaufman Hall experts note these data could illustrate the effects of the start of widespread disenrollment from Medicaid following the end of the PHE and the continuous enrollment provision that accompanied it. As states continue the process of redetermination, these trends will likely continue.

“With states conducting their Medicaid eligibility redetermination, it’s predicted that hundreds of thousands of people will ultimately become uninsured,” said Erik Swanson, senior vice president of Data and Analytics with Kaufman Hall. “The data indicate that we may already be seeing the effects of disenrollment materialize with patients less likely to seek out the care they need and a continued rise in bad debt and charity care.”

Inflation Pressures Hospital Finances

High expenses have been placing added strain on hospitals as they try to recover from the challenges of the pandemic. Labor expense per adjusted discharge increased 3% in April from March, and the costs of goods and services continued to be well above pre-pandemic levels. While total expenses fell slightly in April, operating revenues declined at a faster rate, down 5% month-over-month.

“Hospital and health system leaders must figure out how to navigate the new financial reality and begin to take action,” said Swanson. “In the face of operating margins that may never fully recover and inflated expenses, developing and executing a strategic path forward to a future that is financially sustainable is crucial.”

The National Hospital Flash Report draws on data from more than 900 hospitals from Syntellis Performance Solutions.


About Kaufman Hall 

Kaufman Hall provides management consulting solutions to help society’s foundational institutions realize sustained success amid changing market conditions. Since 1985, Kaufman Hall has been a trusted advisor to boards and executive management teams, helping them incorporate proven methods, rigorous analytics, and industry-leading solutions into their strategic planning and financial management processes, with a focus on achieving their most challenging goals.

Kaufman Hall services use a rigorous, disciplined, and structured approach that is based on the principles of corporate finance. The breadth and integration of Kaufman Hall advisory services are unparalleled, encompassing strategy; financial and capital planning; performance improvement; treasury and capital markets management; mergers, acquisitions, partnerships, and joint ventures; and real estate.

Kaufman Hall companies include Claro Healthcare and Gist Healthcare.

Hospitals Experiencing Effects of Inflation and End of Public Health Emergency | Kaufman Hall